Regulatory News:
Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of December 31, 2018, the following assets appeared on the liquidity account:
- Number of shares: | 66,507 | |
- Cash balance of the liquidity account: | € 164,789.34 |
As a reminder, as of June 30, 2018, the following resources were booked to the liquidity account:
- Number of shares: | 51,934 | |
- Cash balance of the liquidity account: | € 255,399.30 |
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis or Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 28 employees and rights to 16 patent families protecting its technology.
For more information, visit: www.geneuro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005372/en/